• Abba MC, Nunez MI, Colussi AG, Croce MV, Segal-Eiras A, Aldaz CM. 2006. GATA3 protein as a MUC1 transcriptional regulator in breast cancer cells. Breast Cancer Res 8:R64.
  • Bae HJ, Eun JW, Noh JH, Kim JK, Jung KH, Xie HJ, Park WS, Lee JY, Nam SW. 2009. Down-regulation of transforming growth factor beta receptor type III in hepatocellular carcinoma is not directly associated with genetic alterations or loss of heterozygosity. Oncol Rep 22:475480.
  • Blobe GC, Schiemann WP, Lodish HF. 2000. Role of transforming growth factor beta in human disease. N Engl J Med 342:13501358.
  • Cooper SJ, Zou H, Legrand SN, Marlow LA, von Roemeling CA, Radisky DC, Wu KJ, Hempel N, Margulis V, Tun HW, Blobe GC, Wood CG, Copland JA. 2010. Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma. Oncogene 29:29052915.
  • Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC. 2007. The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest 117:206217.
  • Finger EC, Turley RS, Dong M, How T, Fields TA, Blobe GC. 2008. TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis 29:528535.
  • Florio P, Ciarmela P, Reis FM, Toti P, Galleri L, Santopietro R, Tiso E, Tosi P, Petraglia F. 2005. Inhibin alpha-subunit and the inhibin coreceptor betaglycan are downregulated in endometrial carcinoma. Eur J Endocrinol 152:277284.
  • Gatza CE, Oh SY, Blobe GC. 2010. Roles for the type III TGF-beta receptor in human cancer. Cell Signal 22:11631174.
  • Gordon KJ, Blobe GC. 2008. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta 1782:197228.
  • Gordon KJ, Dong M, Chislock EM, Fields TA, Blobe GC. 2008. Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis 29:252262.
  • Hempel N, How T, Cooper SJ, Green TR, Dong M, Copland JA, Wood CG, Blobe GC. 2008. Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta. Carcinogenesis 29:905912.
  • Hempel N, How T, Dong M, Murphy SK, Fields TA, Blobe GC. 2007. Loss of betaglycan expression in ovarian cancer: role in motility and invasion. Cancer Res 67:52315238.
  • Iolascon A, Giordani L, Borriello A, Carbone R, Izzo A, Tonini GP, Gambini C, Della Ragione F. 2000. Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas. Br J Cancer 82:11711176.
  • Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. 2008. Cancer statistics, 2008. CA Cancer J Clin 58:7196.
  • Jiang X, Liu R, Lei Z, You J, Zhou Q, Zhang H. 2010. [Defective expression of TGFBR3 gene and its molecular mechanisms in non-small cell lung cancer cell lines]. Zhongguo Fei Ai Za Zhi 13:451457.
  • Kaufman DS, Shipley WU, Feldman AS. 2009. Bladder cancer. Lancet 374:239249.
  • Liu H, Shi J, Wilkerson ML, Lin F. 2012. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol 138:5764.
  • Liu Z, Li W, Lei Z, Zhao J, Chen XF, Liu R, Peng X, Wu ZH, Chen J, Liu H, Zhou QH, Zhang HT. 2010. CpG island methylator phenotype involving chromosome 3p confers an increased risk of non-small cell lung cancer. J Thorac Oncol 5:790797.
  • Lu F, Zhang HT. 2011. DNA methylation and nonsmall cell lung cancer. Anat Rec (Hoboken) 294:17871795.
  • Molenaar JJ, Ebus ME, Koster J, Santo E, Geerts D, Versteeg R, Caron HN. 2010. Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells. Oncogene 29:27392745.
  • Nguyen AH, Tremblay M, Haigh K, Koumakpayi IH, Paquet M, Pandolfi PP, Mes-Masson AM, Saad F, Haigh JJ, Bouchard M. 2013. Gata3 antagonizes cancer progression in Pten-deficient prostates. Hum Mol Genet 22:24002410.
  • Siegel PM, Massague J. 2003. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3:807821.
  • Tokunaga H, Lee DH, Kim IY, Wheeler TM, Lerner SP. 1999. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. Clin Cancer Res 5:25202525.
  • Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, Wu K, Luxon BA, Sinha M, Anastasiadis PZ, Copland JA. 2010. Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS One 5:e10696.
  • Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC. 2007. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res 67:10901098.